Oak Harvest Investment Services Acquires Shares of 50,000 Teva Pharmaceutical Industries Ltd. $TEVA

Oak Harvest Investment Services bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 50,000 shares of the company’s stock, valued at approximately $1,010,000.

A number of other large investors have also recently modified their holdings of the company. Lansforsakringar Fondforvaltning AB publ grew its stake in Teva Pharmaceutical Industries by 2.2% in the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company’s stock worth $3,844,000 after purchasing an additional 5,344 shares in the last quarter. Trexquant Investment LP lifted its holdings in shares of Teva Pharmaceutical Industries by 114.8% in the 1st quarter. Trexquant Investment LP now owns 203,909 shares of the company’s stock worth $3,134,000 after buying an additional 108,986 shares during the period. Canada Pension Plan Investment Board grew its position in shares of Teva Pharmaceutical Industries by 109.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 150,638 shares of the company’s stock worth $2,315,000 after buying an additional 78,638 shares in the last quarter. Retirement Planning Co of New England Inc. increased its stake in shares of Teva Pharmaceutical Industries by 97.2% during the first quarter. Retirement Planning Co of New England Inc. now owns 31,228 shares of the company’s stock valued at $480,000 after buying an additional 15,393 shares during the period. Finally, Royal Bank of Canada raised its holdings in shares of Teva Pharmaceutical Industries by 0.4% in the first quarter. Royal Bank of Canada now owns 1,181,964 shares of the company’s stock valued at $18,167,000 after acquiring an additional 4,361 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Barclays started coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and a consensus price target of $32.88.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $31.58 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The firm has a market cap of $36.22 billion, a PE ratio of 52.63, a P/E/G ratio of 1.90 and a beta of 0.66. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $31.99. The stock has a fifty day moving average price of $25.87 and a 200-day moving average price of $20.67.

Insiders Place Their Bets

In related news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 in the last three months. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.